跳到主要內容區塊

醫學生物技術暨檢驗學系 (醫技系)

國立陽明交通大學

黃琤

專任副教授 

黃琤     

Cheng Huang

聯絡方式 學歷

☏ 02-2826-7149 (Office);

02-2826-7000 轉65923 (Lab)

 chengh@nycu.edu.tw

〒 Institute of Biotechnology in Medicine, National Yang Ming University, No. 155, Sec. 2, Linong St., Beitou District, Taipei City 112, Taiwan (R.O.C.)

Institute of Biochemistry and Molecular Biology, National Taiwan University College of Medicine, Ph. D.


Institute of Biochemistry and Molecular Biology, National Taiwan University College of Medicine, M. S.

Department of Medical Technology, National Taiwan University College of Medicine, B. S.

 經歷
2017 - present Associate Professor, Department of Biotechnology and Laboratory Science in Medicine, National Yang-Ming University
2015-2017  Associate Research Fellow, National Research Institute of Chinese Medicine
2011-2015  Assistant Research Fellow, National Research Institute of Chinese Medicine
2009-2011 Distinguished Postdoctoral Fellow of NSC (國科會-特約博士後研究學者), Institute of Biochemistry and Molecular Biology, National Taiwan University College of Medicine  
2007 - 2009 Postdoctoral Fellow, Institute of Biochemistry and Molecular Biology, National Taiwan University College of Medicine
研究方向
本實驗室主要研究目的有以下兩個大方向:
  1. 們的研究在於探討肝炎病毒之生活史及其致病機轉,希望透過對這些病毒之瞭解,能開發治療肝炎病毒之新藥。B型肝炎病毒(HBV)會造成人類肝臟急性或慢性的感染;並伴隨著嚴重的肝臟疾病,例如肝硬化及肝癌。D型肝炎病毒(HDV)會與B型肝炎病毒(HBV)共同感染(co-infection)或重疊感染(super-infection),引起嚴重的慢性肝炎,甚至猛爆性肝炎。我們希望瞭解在B型及D型肝炎病毒感染初期,研究宿主細胞運輸作用參與在B型及D型肝炎病毒生活史中的功能角色,進一步,我們也將研究B型及D型肝炎病毒在宿主細胞上的受體NTCP蛋白與病毒之間的作用關係。透過這個研究,除了有助於B型及D型肝炎病毒致病機轉的了解之外,並且可作為病毒藥物開發的模式。
  2. 目前已知肥胖和胰島素失調與許多疾病間存在關聯性,例如心血管疾病、第二型糖尿病、脂肪肝等等,這類疾病常涉及脂類代謝異常或醣類代謝異常。舉例而言,脂肪肝屬於非酒精性脂肪肝疾病的初始階段,是一種現代人常見的代謝症狀,主要是由脂質代謝失衡所造成。目前已有為數不少的臨床經驗顯示,脂肪肝會導致肝硬化,並且伴隨著脂肪性肝炎及肝壞死等問題的發生。我們的研究在於發展新藥在治療代謝疾病之用途,利用疾病小鼠之模型,希望可以改善多種新陳代謝疾病
  1.     Hepatitis B virus (HBV) causes acute and chronic infections in humans; such infections are often associated with severe liver diseases, including cirrhosis and hepatocellular carcinoma (HCC). Hepatitis delta virus (HDV) causes fulminant hepatitis and progressive chronic liver cirrhosis in patients superinfected or coinfected with HBV. We examined the roles of clathrin-mediated trafficking pathway involved in the life cycle of HBV/HDV. In addition, the receptor on the plasma membrane which is required for the infection of HBV/HDV is NTCP. We have established HBV/HDV infection model in vitro and in vivo. Our model will help us to develop new drugs for treatment of HBV/HDV infection. Our study suggests new strategies for manipulating HBV/HDV for therapeutic purposes in treating disorders associated with liver injury and cirrhosis.
  2.      Obesity and dysregulated insulin action in the liver are strongly associated and are currently a worldwide health problem. Fatty liver, the initial stage of nonalcoholic fatty liver disease (NAFLD), is a common metabolic symptom, and is caused by an imbalance of lipid metabolism. The purpose of our proposal is to develop drugs for metabolic syndrome. We will design a process of pharmacology experiments for development of new drugs. In addition, we will complete additional safety evaluation for new drugs.
指導學生獲獎

2020

學生邱韋中、呂翊萱、楊昕宜之研究成果在Biochemical and Biophysical Research Communications發表

2020

博士後研究員林育君研究成果在BMC Complementary and Alternative Medicine發表

2020

學生邱韋中研究成果在Journal of Enzyme Inhibition and Medicinal Chemistry發表

2020

博士生張廷禎、學生邱韋中、賴威翰研究成果在Pharmacological Research發表

2020

碩士生賴威翰 2020年台加全穀豆類營養保健與創新加工國際研討會 論文競賽-第二名

2020

碩士生黃昕 陽明大學2020年學術論文比賽-優等獎

2020

碩士生田筱萱 陽明大學2020年學術論文比賽-佳作獎

2020

大專生許珮甄 榮獲科技部大專生專題研究計畫

2020

碩士生黃昕 陽明醫技所論文比賽-第二名

2020

碩士生江豪和田筱萱 研究成果Evidence-Based Complementary and Alternative Medicine發表

2020

碩士生田筱萱 榮獲農委會補助碩士班參加 The ICBC Conference國際研討會(紐西蘭),並發表口頭演講

2020

碩士生田筱萱 研究成果在Journal of Ginseng Research發表

2019

博士生張廷禎、碩士生江豪 研究成果在BMC Complementary and Alternative Medicine發表

2019

碩士生江豪和黃昕 研究成果在British Journal of Pharmacology發表

2019

大專生陳柏辛 榮獲科技部大專生專題研究計畫

2019

大專生范雅淇 榮獲科技部大專生專題研究計畫

2019

碩士生江豪和田筱萱 2019年穀物國際研討會海報論文競賽-第一名金獎

2019

碩士生江豪 陽明大學2019年學術論文比賽-優等獎

2019

碩士生江豪 陽明醫技所尹珣若論文比賽-全校前九名入圍獎

2019

碩士生江豪 陽明醫技所論文比賽-第一名

2018

大專生田筱萱 榮獲科技部大專生專題研究計畫

研究著作
  1. Ting-Chen Chang, Wei-Chung Chiou, Wei-Han Lai, Hsiu-Chen Huang, Yu-Ling Huang, Hui-Kang Liu, Yu-Chih Liang, and Cheng Huang*. (2021) Ugonin J improves metabolic disorder and ameliorates nonalcoholic fatty liver disease by regulating the AMPK/AKT signaling pathway. Pharmacological Research. 163: 105298 (* Corresponding author) (IF=5.893; Pharmacology & Pharmacy, 19/271=7.0%)
  2. Wei-Chung Chiou, Meng-Shiuan Hsu, Yun-Ti Chen, Jinn-Moon Yang, Yeou-Guang Tsay, Hsiu-Chen Huang, and Cheng Huang*. (2021) Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. Journal of Enzyme Inhibition and Medicinal Chemistry. 36:1, 147-153 (* Corresponding author) (IF=4.673; Chemistry & Medicinal, 9/61=14.7%)

  3. Hsiu-Chen Huang, Chiung-Ju Chen, Yu-Heng Lai, Yu-Chun Lin, Wei-Chung Chiou, Hsu-Feng Lu, Ying-Fang Chen, Yu-Hsin Chen, and Cheng Huang*.(2021) Momordica cochinchinensis Aril Ameliorates Diet-induced Metabolic Dysfunction and Nonalcoholic Fatty Liver by Modulating Gut Microbiota. International Journal of Molecular Sciences. [Accepted] (* Corresponding author) (IF=4.556; BIOCHEMISTRYMOLECULAR BIOLOGY, 74/297, 24.9%)

  4. Hao Chiang, Jinq-Chyi Lee, Hsiu-Chen Huang, Hsing Huang, Hui-Kang Liu, and Cheng Huang*. (2020) Delayed intervention with a novel SGLT2 inhibitor NGI001 suppresses diet-induced metabolic dysfunction and nonalcoholic fatty liver disease in mice. British Journal of Pharmacology. 177: 239-253. (* Corresponding author) (IF=7.730; Pharmacology & pharmacy, 9/271=3.3%)

  5. Hsu-Feng Lu, Yu-Heng Lai, Hsiu-Chen Huang, I-Jung Lee, Lie-Chwen Lin, Hui-Kang Liu, Hsiao-Hsuan Tien, and Cheng Huang*. (2020) Ginseng-plus-Bai-Hu-Tang ameliorates diet-induced obesity, hepatic steatosis and insulin resistance in mice. Journal of Ginseng Research. 44: 238-246 (* Corresponding author) (IF=5.487; Integrative & complementary medicine, 1/28=3.5%)

  6. Wei-Chung Chiou, Jui-Chieh Chen, Yun-Ti Chen, Jinn-Moon Yang, Lih-Hwa Hwang, Yi-Shuan Lyu, Hsin-Yi Yang, Cheng Huang*. (2020) The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease. Biochemical and Biophysical Research Communications. [Accepted] (* Corresponding author) (IF=2.985;  Biophysics, 26/71=36.6%)

  7. Yu-Chun Lin, Hsu-Feng Lu, Jui-Chieh Chen, Hsiu-Chen Huang, Yu-Hsin Chen, Yen-Shuo Su, Chien-Yi Tung, Cheng Huang*. (2020) Purple-leaf Tea (Camellia sinensis L.) Ameliorates High-fat Diet Induced Obesity and Metabolic Disorder through the Modulation of the Gut Microbiota in Mice. BMC Complementary and Alternative Medicine. [Accepted] (* Corresponding author) (IF=2.833; Integrative & complementary medicine, 6/28=21.42%)

  8. Hao Chiang, Hsu-Feng Lu, Jui-Chieh Chen, Yu-Hsin Chen, Hsi-Tai Sun, Hsiu-Chen Huang, Hsiao-Hsuan Tien, and Cheng Huang*. (2020) Adlay Seed (Coix lacryma-jobi L.) Extracts Exhibit a Prophylactic Effect on Diet-Induced Metabolic Dysfunction and Nonalcoholic Fatty Liver Disease in Mice. Evidence-Based Complementary and Alternative Medicine. 2020:9519625. doi: 10.1155/2020/9519625. (* Corresponding author) (IF=1.813; Integrative & complementary medicine, 16/28=57.1%)

  9. Ting-Chen Chang, Hao Chiang, Yu-Heng Lai, Yu-Ling Huang, Hsiu-Chen Huang, Yu-Chih Liang, Hui-Kang Liu,  and Cheng Huang*. (2019) Helminthostachys zeylanica alleviates hepatic steatosis and insulin resistance in diet-induced obese mice. BMC Complementary and Alternative Medicine. 19: 368-378 (* Corresponding author) (IF=2.833; Integrative & complementary medicine, 6/28=21.42%)

  10. Cheng Huang*, Hsu-Feng Lu, Yu-Hsuan Chen, Jui-Chieh Chen, Wen-Hsiang Chou, Hsiu-Chen Huang. (2020) Curcumin, demethoxycurcumin, and bisdemethoxycurcumin induced caspase-dependent and –independent apoptosis via Smad or Akt signaling pathways in HOS cells. BMC Complementary and Alternative Medicine. 20(1):68 (*Co-first author) (IF=2.833; Integrative & complementary medicine, 6/28=21.42%)

  11. Ming-Ju Hsieh, Cheng Huang*, Chia-Chieh Lin, Chih-Hsin Tang, Chih-Yang Lin, I-Neng Lee, Hsiu-Chen Huang, and Jui-Chieh Chen. (2019) Basic fibroblast growth factor promotes doxorubicin resistance in chondrosarcoma cells by affecting XRCC5 expression. Molecular Carcinogenesis. 59: 293-303 (*Co-first author) (IF=3.411; Biochemistry & Molecular Biology, 119/299=39.8%)

  12. Ming‑Ju Hsieh, Yin‑Hong Chen, I‑Neng Lee, Cheng Huang, Yu‑Ju Ku and Jui‑Chieh Chen. (2019) Secreted amphiregulin promotes vincristine resistance in oral squamous cell carcinoma. International Journal of Oncology. 55: 949-959

  13. Jui-Chieh Chen, I-Neng Lee, Cheng Huang, Yu-Ping Wu, Chiu-Yen Chung, Ming-Hsueh Lee, Martin Hsiu-Chu Lin, Jen-Tsung Yang. (2019) Valproic acid-induced amphiregulin secretion confers resistance to temozolomide treatment in human glioma cells. BMC Cancer. 19(1):756-760

  14. Lie-Chwen Lin, Lin-Chien Lee, Cheng Huang, Chiung-Tong Chen, Jen-Shin Song, Young-Ji Shiao, Hui-Kang Liu. (2019) Effects of Boschnaloside from Boschniakia rossica on dysglycemia and islet dysfunction in severely diabetic mice through modulating the action of glucagon-like peptide-1. Phytomedicine. 62: 152946-152956

  15. Cheng Huang, Yu-Ling Huang, Chia-Chi Wang, Yi-Ling Pan, Yu-Heng Lai, and Hsiu-Chen Huang. (2019) Ampelopsin A and ampelopsin C induce apoptosis and metastasis through down-regulating AxL, TYRO3, and FYN expressions in MDA-MB-231 breast cancer cells. Journal of Agricultural and Food Chemistry. 67(10):2818-2830 (First author) (IF=3.571; Agriculture, multidisciplinary, 3/56=5.4%)

  16. Yen-Chang Lin, Cheng Huang*, Hsiu-Chen Huang, Ming-Ting Liao, Yu-HengLai. (2019) Metabolomics profiling of haloperidol and validation of thromboxane-related signaling in the early development of zebrafish.  Biochem Biophys Res Commun. 513(3):608-615 (* Co-first author) (IF=2.705; Biophysics, 28/72=38.9%)

  17. Yu-Chun Lin, Cheng Huang, Hsin-Chih Lai. (2019) Revealing the ultrastructure of the membrane pores of intact Serratia marcescens cells by atomic force microscopy. Heliyon. 5:e02636

  18. Jui-Chieh Chen, Cheng Huang, I-Neng Lee, Yu-Ping Wu, Chih-Hsin Tang. (2018) Amphiregulin enhances cell migration and resistance to doxorubicin in chondrosarcoma cells through the MAPK pathway. Molecular Carcinogenesis. 57(12):1816-1824

  19. Han-Min Chen, Lin-Chien Lee, Kuang-Yu Hu, Wei-Jern Tsai, Cheng Huang, Hui-Jen Tsay, Hui-Kang Liu. (2018) The Application of Post-Translational Modification Oriented Serum Proteomics to Assess Experimental Diabetes with Complications. PLOS ONE. 13(11):e0206509

  20. Yu-Heng Lai, Cheng-Pu Sun, Hsiu-Chen Huang, Jui-Chieh Chen, Hui-Kang Liu and Cheng Huang*. (2018) Epigallocatechin gallate inhibits hepatitis B virus infection in human liver chimeric. BMC Complementary and Alternative Medicine. 18:248-254 (* Corresponding author) (IF=2.833; Integrative & complementary medicine, 6/28=21.42%)

  21. Liu GT, Kung HN, Chen CK, Huang C, Wang YL, Yu CP, Lee CP. (2018) Improving nuclear envelope dynamics by EBV BFRF1 facilitates intranuclear component clearance through autophagy. FASEB Journal. 32(7):3968-3983

  22. Hsiu-Chen Huang, Hsu-Feng Lu, Yu-Heng Lai, Chung-Pei Lee, Hui-Kang Liu, and Cheng Huang*. (2017) Tat-enhanced delivery of the C terminus of HDAg-L inhibits assembly and secretion of hepatitis D virus. Antiviral Research. 150:69-78 (* Corresponding author) (IF=4.101; Pharmacology & pharmacy, 56/270=20.7%)

  23. Huang HC, Lee CP, Liu HK, Chang MF, Lai YH, Lee YC, Huang C*. (2016) Cellular Nuclear Export Factors TAP and Aly Are Required for HDAg-L-mediated Assembly of Hepatitis Delta Virus. Journal of Biological Chemistry. 291(50):26226-26238. (* Corresponding author) (IF=4.238; Biochemistry & molecular biology, 87/297=29.3%)

  24. Tseng TS, Chuang SM, Hsiao NW, Chen YW, Lee YC, Lin CC, Huang C, Tsai KC. (2016) Discovery of a potent cyclooxygenase-2 inhibitor, S4, through docking-based pharmacophore screening, in vivo and in vitro estimations. Molecular Biosystems. 12(8):2541-51. doi: 10.1039/c6mb00229c.

  25. Huang C, Wei YX, Shen MC, Tu YH, Wang CC, Huang HC. (2016) Chrysin, Abundant in Morinda citrifolia Fruit Water-EtOAc Extracts, Combined with Apigenin Synergistically Induced Apoptosis and Inhibited Migration in Human Breast and Liver Cancer Cells. Journal of Agricultural and Food Chemistry. 64:4235-45 (First author) (IF=3.571; Agriculture, multidisciplinary, 3/56=5.4%)

  26. Cheng Huang*, Chung-Kuang Lu, Ming-Chin Tu, Jia-Hua Chang, Yen-Ju Chen, Yu-Hsuan Tu, and Hsiu Chen Huang. (2016) Polyphenol-rich Avicennia marina leaf extracts induce apoptosis in human breast and liver cancer cells and in a nude mouse xenograft model. Oncotarget. 7(24):35874-35893. doi: 10.18632/oncotarget.8624. (* First author)

  27. Hui-Kang Liu, Tzu-Min Hung, Hsiu-Chen Huang, I-Jung Lee, Chia-Chuan Chang, Jing-Jy Cheng, Lie-Chwen Lin, and Cheng Huang*. (2015) Bai-Hu-Jia-Ren-Shen-Tang Decoction Reduces Fatty Liver by Activating AMP-activated Protein Kinase In Vitro and In Vivo. Evidence-Based Complementary and Alternative Medicine. doi:10.1155/2015/651734  (* Corresponding author) (IF=1.984; Integrative & complementary medicine, 10/27=37.0%)

  28. Cheng Huang*, Yi-Jing Chen, Wei-Jen Chen, Chih-Li Lin, Yu-Xuan Wei, and Hsiu-Chen Huang. (2015) Combined treatment with chrysin and 1,2,3,4,6-penta-O-galloyl-β-D-glucose synergistically inhibits LRP6 and Skp2 activation in triple-negative breast cancer and xenografts. Molecular carcinogenesis. 54:1613-25 (* First author) (IF=3.411; Biochemistry & Molecular biology, 119/298=39.9%)

  29. Hsiu-Chen Huang, Mi-Hua Tao, Tzu-Min Hung, Jui-Chieh Chen, Zi-Jun Lin, Cheng Huang*. 2014(-)-Epigallocatechin-3-gallate Inhibits Entry of Hepatitis B Virus into Hepatocytes. Antiviral Research. 111:100-111 (* Corresponding author) (IF=4.130; Pharmacology & pharmacy, 50/267=18.7%)

  30. Sheng-Fan Wang, Yueh-Ching Chou, Nirmal Mazumder, Fu-Jen Kao, Leslie D. Nagy, F. Peter Guengerich, Cheng Huang, Hsin-Chen Lee, Ping-Shan Lai, Yune-Fang Ueng. (2013) 7-Ketocholesterol induces P-glycoprotein through PI3K/mTOR signaling in hepatoma cells. Biochemical Pharmacology 86(4):548-60.

  31. Huang C*, Lee SY, Lin CL, Tu TH, Chen LH, Chen YJ, and Huang HC. (2013) Co-treatment with Quercetin and 1,2,3,4,6-Penta-O-galloyl-β-d-glucose Causes Cell Cycle Arrest and Apoptosis in Human Breast Cancer MDA-MB-231 and AU565 Cells. Journal of Agricultural and Food Chemistry 61: 6430−6445 (* First author) (IF=3.571; Agriculture, multidisciplinary, 3/56=5.4%)

  32. Cheng Huang*, Jia-Yin Jiang, Shin C. Chang, Yeou-Guang Tsay, Mei-Ru Chen, and Ming-Fu Chang. (2013) NESI Protein Forms Complexes with Lamin A/C-Nups to Mediate the CRM1-Independent Nuclear Export of Large Hepatitis Delta Antigen. Journal of Virology. 87:1596-604 (* First author) (IF=4.324; Virology, 8/36=22.2%)

  33. Pei-Yun Chuang, Cheng Huang, and Hsiu-Chen Huang. (2013) The use of a combination of tamoxifen and doxorubicin synergistically to induce cell cycle arrest in BT483 cells by down-regulating CDK1, CDK2 and cyclin D expression. Journal of Pharmaceutical Technology & Drug Research 2: 1-4

  34. Hsiu-Chen Huang, Chun-Chi Chen, Wen-Cheng Chang, Mi-Hua Tao, and Cheng Huang*. (2012) Entry of Hepatitis B Virus into Immortalized Human Primary Hepatocytes by Clathrin-Dependent Endocytosis. Journal of Virology. 86:9443-9453 (* Corresponding author) (IF=4.324; Virology, 8/36=22.2%)

  35. Shih-Han Sun, Hsiu-Chen Huang, Cheng Huang, Jen-Kun Lin. (2012) Cycle arrest and apoptosis in MDA-MB-231/Her2 cells induced by curcumin. European Journal of Pharmacology. 690:22-30

  36. Cheng Huang*, Shin C. Chang, Hui-Chin Yang, Chung-Liang Chien, and Ming-Fu Chang (2009) Clathrin-mediated post-Golgi trafficking in the morphogenesis of hepatitis delta virus. Journal of Virology. 83:12314-12324 (* First author) (IF=4.324; Virology, 8/36=22.2%)

  37. Tzu-Min Hung, Shin C. Chang, Wei-Hsuan Yu, Yu-Wen Wang, Cheng Huang, Shao-Chun Lu, Po-Huang Lee, and Ming-Fu Chang (2009) A novel nonsynonymous variant of matrix metalloproteinase-7 confers risk of liver cirrhosis. Hepatology. 50:1184-1193

  38. Cheng Huang*, Shin C. Chang, I-Chen Yu, Yeou-Guang Tsay, and Ming-Fu Chang (2007) Large hepatitis delta antigen is a novel clathrin adaptor-like protein. Journal of Virology. 81:5985-5994. A Highlights from JV Selection. (* First author) (IF=4.324; Virology, 8/36=22.2%)

  39. Yun-Hsin Wang, Shin C. Chang, Cheng Huang, Ya-Ping Li, Chia-Huei Lee, and Ming-Fu Chang. (2005) Novel nuclear export signal interacting protein, NESI, critical for the assembly of hepatitis delta virus. Journal of Virology. 79:8113-8120

專利
  1. 具有GLP-1受體調控活性之化合物及其用途/ 發明第I 511963/ 中華民國專利 (2015)
  2. 具有GLP-1受體調控活性之化合物及其用途/ ZL 2014 1 0584351.1/ 中國大陸專利 (2017)

  3. 錫蘭七指蕨、入地蜈蚣素及黃酮類化合物用於治療或預防新陳代謝疾病之用途/ 發明第I 621440/中華民國專利 (2018)

  4. 錫蘭七指蕨、入地蜈蚣素及黃酮類化合物用於治療或預防新陳代謝疾病之用途/ I1025-0004-US/ 美國專利 (2019)

  5. Compounds and methods for prevention and treatment of coronavirus infections. (U.S. Patent Application Number: 63/071564) (2020)

  6. Compounds and methods for prevention and treatment of coronavirus infections. (U.S. Patent Application Number: 63/018690) (2020)

  7. POTENTIAL FDA-APPROVED DRUGS IN INHIBITING SARS-COV-2 3CL PROTEASE TO TREAT COVID-19. (U.S. Patent Application Number: 63/020127) (2020)